Table 3 Univariate analysis of overall survival among EOC patients
Variable | Category | N(%) | OS (Median[IQR]) | Survival rate(%) | P |
|---|---|---|---|---|---|
Age y | <49 | 138 (45.39) | 69.5 [38,102] | 84.06 | 0.0013* |
> = 49 | 166 (54.61) | 53 [23,78] | 71.08 | ||
Menopausal status | Pre | 161 (52.96) | 68 [38,102] | 81.99 | 0.0043* |
Post | 143 (47.04) | 53 [22,77] | 71.33 | ||
Gravidity | 0 | 35 (11.51) | 60 [34,107] | 82.86 | 0.3070 |
> = 1 | 269 (88.49) | 60 [27,89] | 75.84 | ||
Parity | 0 | 51 (16.78) | 70 [40,96] | 84.31 | 0.1016 |
> = 1 | 253 (83.22) | 58 [26,86] | 75.1 | ||
Stage | Early | 185 (60.86) | 69 [47,102] | 91.35 | <.0001* |
Late | 119 (39.14) | 38 [18,72] | 53.78 | ||
FIGO Stage | I | 141 (46.38) | 72 [51,102] | 95.74 | <.0001* |
II | 44 (14.47) | 60 [33,110] | 79.55 | ||
III | 104 (34.21) | 41.5 [20,73.5] | 53.85 | ||
IV | 15 (4.93) | 10 [5,53] | 53.33 | ||
Histotype | Clear cell | 118 (38.82) | 58.5 [27,88] | 78.81 | 0.6479 |
Endometrioid | 186 (61.18) | 60.5 [31,92] | 75.81 | ||
Lymphadenectomy | Yes | 51 (16.78) | 38 [12,69] | 52.94 | <.0001* |
No | 253 (83.22) | 62 [34,91] | 81.82 | ||
Metastasis of LN | Positive | 40 (13.16) | 32.5 [15,59] | 57.5 | <.0001* |
Negative | 213 (70.07) | 68 [44,101] | 86.38 | ||
Residual disease | >1 cm | 73 (24.01) | 33 [15,65] | 50.68 | <.0001* |
None or <1 cm | 231 (75.99) | 66 [38,98] | 85.28 | ||
CA125 normal | Yes | 55 (18.09) | 73 [52,102] | 92.73 | 0.0009* |
No | 249 (81.91) | 58 [24,87] | 73.49 | ||
Tumor size(cm) | <10 | 153 (50.33) | 60 [32,90] | 77.12 | 0.8933 |
≥10 | 151 (49.67) | 60 [26,88] | 76.82 | ||
Tumor side | Unilateral | 212 (69.74) | 61 [33.5,96.5] | 80.66 | 0.0063* |
Bilateral | 92 (30.26) | 53 [24,84.5] | 67.39 | ||
Endometriosis | No | 235 (77.30) | 57 [24,88] | 72.77 | 0.0010* |
Yes | 69 (22.70) | 67 [42,101] | 91.3 | ||
Endometrial disorders | No | 252 (82.89) | 60 [29.5,91] | 75.0 | 0.2184 |
Yes | 52 (17.11) | 60 [29,85.5] | 84.62 | ||
Endometrial cancer | No | 252 (82.89) | 60 [26.5,91] | 74.6 | 0.2321 |
Yes | 27 (8.88) | 60 [40,96] | 85.19 | ||
Hypertension | No | 250 (82.24) | 60 [32,92] | 79.6 | 0.0132* |
Yes | 54 (17.76) | 57.5 [19,81] | 64.81 | ||
Chemotherapy cycle | <4 | 191 (62.83) | 61 [34,91] | 80.1 | 0.0373* |
≥4 | 100 (32.89) | 53 [23.5,85] | 70 | ||
Chemo-resistance | No | 252 (82.89) | 67 [44,99.5] | 84.52 | <.0001* |
Yes | 52 (17.11) | 19 [11,28.5] | 40.38 |